BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Bausch Health Companies Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$6.32+0.02 (+0.32%)
Close on Oct 19, 2026
- Market cap
- $2.39B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.27 (+4.46%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Bausch Health Companies Inc. grew revenue 10.1% to $10.85B over the twelve months to Jun 30, 2026. Operating income fell 44.7% to $883.00M, moving the operating margin from 16.2% to 8.1%. Free cash flow was $1.43B, up 28.3% from a year earlier.
Revenue
$10.85B
+10.1% vs. a year earlier
Operating income
$883.00M
-44.7% vs. a year earlier
Free cash flow
$1.43B
+28.3% vs. a year earlier
EPS, diluted
-$2.96
-1238.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.39B
- P/E ratio
- –
- Price to sales
- 0.22
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 59.88%
Fundamentals
- Revenue
- $10.85B
- Net income
- -$1.10B
- EPS, diluted
- -$2.96
- Free cash flow
- $1.43B
- Book value per share
- -$4.68
- Diluted shares
- 378M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$10.85B+10.1% YoY
Gross profit
–
Operating income
$883.00M-44.7% YoY
Net income
-$1.10B-1220.4% YoY
EPS, diluted
-$2.96-1238.5% YoY
Free cash flow
$1.43B+28.3% YoY
Reported periodTrailing twelve months